Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Ind Swift Lab
Join Channel
Consolidated Standalone

Ind-Swift Lab.

₹107.1 1.4 | 1.3%

Market Cap ₹633 Cr.

Stock P/E 14.3

P/B 1.1

Current Price ₹107.1

Book Value ₹ 95.7

Face Value 10

52W High ₹138.3

Dividend Yield 0%

52W Low ₹ 63.4

Edit Ratio

Ind-Swift Lab. Research see more...

Overview Inc. Year: 1995Industry: Pharmaceuticals & Drugs

Ind-Swift Laboratories Ltd is an primarily India-based corporation, which is engaged in production of active pharmaceutical components (APIs). The Company operates through the bulk tablets and pharmaceuticals segment. The Company has a product portfolio of approximately 50 products across about 15 therapeutic segments. It manufactures Atorvastatin Calcium Crystalline, Clarithromycin powder/granules, Roxithromycin and Nitazoxanide. It also manufactures Moxifloxacin, Imatinib Mesylate, Nateglinide, and Dutasteride,. The Company gives products for various therapeutic classes, such as macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsyhotic, bone resorption inhibitor, hyperparathyrodism, antineoplastic, remedy of premature ejaculation and nootropic. Its research and improvement tasks consist of Crams for API Development Medicinal Chemistry development for various discovery projects. The Company also operates a menthol and mint products production facility.

Read More..

Ind-Swift Lab. Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Ind-Swift Lab. Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 236 247 307 280 310 313 304 310 290 288
Other Income 7 8 21 7 8 8 10 6 7 7
Total Income 243 255 328 288 318 321 314 316 297 295
Total Expenditure 180 194 270 227 251 259 240 250 224 236
Operating Profit 63 61 58 60 66 62 75 66 73 59
Interest 24 24 23 24 24 22 22 20 21 21
Depreciation 14 21 82 16 16 15 9 14 13 14
Exceptional Income / Expenses 0 0 0 0 0 0 -27 0 0 0
Profit Before Tax 25 16 -47 20 26 24 17 32 39 24
Provision for Tax 1 -0 14 0 1 -3 41 14 7 5
Profit After Tax 24 16 -61 20 25 28 -24 17 32 20
Adjustments 0 0 0 -0 0 -0 -0 -0 -0 -0
Profit After Adjustments 24 16 -61 20 25 27 -24 17 32 19
Adjusted Earnings Per Share 4.1 2.7 -10.4 3.4 4.3 4.7 -4.1 2.9 5.4 3.3

Ind-Swift Lab. Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 1136 965 660 653 697 763 757 780 891 1039 1207 1192
Other Income 18 14 22 16 23 26 37 33 23 43 33 30
Total Income 1154 979 683 669 720 788 794 813 914 1082 1241 1222
Total Expenditure 1065 906 572 546 591 628 630 636 709 843 978 950
Operating Profit 89 73 111 123 129 160 163 177 206 239 263 273
Interest 140 117 117 106 90 35 92 107 100 96 92 84
Depreciation 54 66 84 85 88 87 104 90 87 131 57 50
Exceptional Income / Expenses -14 -33 -53 -15 -5 -2 83 0 0 0 -27 -27
Profit Before Tax -119 -142 -143 -83 -55 36 50 -20 18 13 87 112
Provision for Tax -1 -20 -24 -24 -16 14 21 1 21 15 39 67
Profit After Tax -118 -122 -119 -59 -39 22 29 -21 -3 -2 48 45
Adjustments 0 0 0 0 0 0 0 0 0 0 -0 0
Profit After Adjustments -118 -122 -119 -59 -39 22 29 -21 -3 -2 48 44
Adjusted Earnings Per Share -30 -29.8 -29.1 -14.3 -8.7 4.9 6.1 -3.6 -0.5 -0.4 8.1 7.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 16% 16% 10% 1%
Operating Profit CAGR 10% 14% 10% 11%
PAT CAGR 0% 0% 17% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 63% 9% 24% 11%
ROE Average 11% 3% 3% -9%
ROCE Average 13% 10% 9% 5%

Ind-Swift Lab. Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 853 725 595 517 531 553 588 641 604 601 682
Minority's Interest 0 0 0 0 0 0 0 0 -0 -0 0
Borrowings 820 964 816 746 592 520 966 891 884 848 753
Other Non-Current Liabilities 39 19 -5 -29 -97 -83 -64 -63 -44 -34 -11
Total Current Liabilities 663 630 833 951 1005 936 356 323 315 334 371
Total Liabilities 2376 2339 2239 2185 2031 1927 1845 1792 1758 1749 1794
Fixed Assets 1171 1174 1117 1099 1033 925 901 843 739 628 585
Other Non-Current Assets 180 176 202 165 170 163 108 86 75 46 45
Total Current Assets 1025 989 920 922 829 839 836 863 942 1073 1163
Total Assets 2376 2339 2239 2185 2031 1927 1845 1792 1758 1749 1794

Ind-Swift Lab. Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 47 18 21 20 23 16 9 30 11 12 21
Cash Flow from Operating Activities -47 66 98 79 96 73 -64 125 135 150 195
Cash Flow from Investing Activities -48 -27 -36 -30 -31 -17 -12 -9 -10 5 -13
Cash Flow from Financing Activities 66 -38 -64 -48 -69 -62 100 -133 -124 -141 -186
Net Cash Inflow / Outflow -29 0 -1 2 -4 -6 23 -17 1 14 -4
Closing Cash & Cash Equivalent 18 21 20 22 16 9 30 11 12 26 17

Ind-Swift Lab. Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) -30.02 -29.79 -29.14 -14.33 -8.75 4.85 6.09 -3.59 -0.53 -0.36 8.06
CEPS(Rs) -16.18 -13.73 -8.56 6.36 10.98 23.98 27.96 11.66 14.24 21.81 17.8
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 125.78 93.07 67.21 56.78 58.08 65.58 73.01 70.21 66.35 68.33 84.25
Core EBITDA Margin(%) 6.2 5.99 13.03 15.94 14.79 17.41 16.6 18.32 20.35 18.66 18.9
EBIT Margin(%) 1.81 -2.58 -3.83 3.51 4.88 9.26 18.68 11.09 13.16 10.31 14.74
Pre Tax Margin(%) -10.3 -14.45 -21.05 -12.3 -7.72 4.67 6.54 -2.52 2.01 1.2 7.14
PAT Margin (%) -10.22 -12.41 -17.53 -8.72 -5.46 2.85 3.81 -2.71 -0.35 -0.21 3.94
Cash Profit Margin (%) -5.51 -5.72 -5.15 3.87 6.86 14.1 17.5 8.79 9.37 12.3 8.68
ROA(%) -5.13 -5.18 -5.22 -2.65 -1.86 1.11 1.53 -1.17 -0.18 -0.12 2.7
ROE(%) -21.56 -27.88 -36.36 -23.11 -15.89 7.89 8.99 -5.56 -0.78 -0.54 10.61
ROCE(%) 1.24 -1.46 -1.52 1.4 2.19 4.59 9.25 5.97 8.31 7.88 13.25
Receivable days 113.33 158.98 223.2 206.44 185.94 181.25 182.19 174.12 168.41 154.46 144.51
Inventory Days 149.59 153.77 194.38 190.95 178.26 156.48 152.15 153.65 145.99 140.01 130.51
Payable days 91.55 100.84 155.81 137.79 109.26 107.94 115.52 120.5 110.78 106.89 105.77
PER(x) 0 0 0 0 0 11.81 6.45 0 0 0 6.86
Price/Book(x) 0.36 0.42 0.47 0.8 0.57 0.87 0.54 0.31 1.09 0.97 0.66
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 1.23 1.55 2.31 2.48 1.97 2.04 1.68 1.47 1.59 1.26 0.96
EV/Core EBITDA(x) 15.67 20.44 13.72 13.16 10.69 9.72 7.8 6.49 6.9 5.49 4.42
Net Sales Growth(%) -19.38 -15.05 -31.57 -1.09 6.76 9.33 -0.78 3.05 14.33 16.54 16.23
EBIT Growth(%) -87.85 -221.68 -2.59 190.68 47.94 104.1 98.86 -38.78 36.08 -8.58 65.33
PAT Growth(%) -232.24 -3.49 2.17 50.83 33.32 156.15 31.72 -173.2 85.15 31.72 2325.72
EPS Growth(%) -227.77 0.79 2.17 50.83 38.95 155.49 25.37 -158.93 85.15 31.71 2314.85
Debt/Equity(x) 2.51 3.56 5.12 6.25 4.77 4.38 3.21 2.48 2.56 2.33 1.71
Current Ratio(x) 1.55 1.57 1.1 0.97 0.82 0.9 2.35 2.67 2.99 3.21 3.13
Quick Ratio(x) 0.87 0.97 0.69 0.59 0.48 0.56 1.46 1.61 1.8 1.93 1.95
Interest Cover(x) 0.15 -0.22 -0.22 0.22 0.39 2.02 1.54 0.81 1.18 1.13 1.94
Total Debt/Mcap(x) 7.03 8.55 10.86 7.79 8.39 5.03 5.97 8.04 2.36 2.4 2.61

Ind-Swift Lab. Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 42 42 42 42 42 42 42 42 42 42
FII 0.22 0.06 0 0 0.04 0 0.08 0.17 0.31 0.25
DII 19.49 19.49 19.49 19.49 19.49 19.49 19.49 19.49 18.73 8.03
Public 38.29 38.44 38.5 38.5 38.47 38.5 38.43 38.33 38.95 49.72
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 106.89 to 105.77days.
  • Company has reduced debt.

Cons

  • Promoter holding is low: 42%.
  • Company has a low return on equity of 3% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Ind-Swift Lab. News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!